In 2023, the trade exchange (includes international purchases and sales) of Medicaments (Excluding Goods of Heading 3002, 3005 or 3006) Consisting of Mixed together for Therapeutic or Prophylactic Uses, not in Measured Doses or put up for Retail was US$138M.
In 2023, the states with the most international sales in Medicaments (Excluding Goods of Heading 3002, 3005 or 3006) Consisting of Mixed together for Therapeutic or Prophylactic Uses, not in Measured Doses or put up for Retail were Ciudad de México (US$6.21M) and Jalisco (US$163k).
The states with the most international purchases in 2023 were Ciudad de México (US$49.2M), Jalisco (US$37.2M), Estado de México (US$27.9M), Coahuila de Zaragoza (US$5.66M), and Querétaro (US$2.32M).
In 2023, the main commercial destinations of Medicaments (Excluding Goods of Heading 3002, 3005 or 3006) Consisting of Mixed together for Therapeutic or Prophylactic Uses, not in Measured Doses or put up for Retail were India (US$2.62M), United States (US$2.33M), Morocco (US$1.02M), Venezuela (US$106k), and Guatemala (US$81.4k).
The main commercial origins of Medicaments (Excluding Goods of Heading 3002, 3005 or 3006) Consisting of Mixed together for Therapeutic or Prophylactic Uses, not in Measured Doses or put up for Retail in 2023 were India (US$37.6M), China (US$36.4M), United States (US$13.3M), Germany (US$8.54M), and France (US$7M).
In the global context, the main exporting countries of Medicaments (Excluding Goods of Heading 3002, 3005 or 3006) Consisting of Mixed together for Therapeutic or Prophylactic Uses, not in Measured Doses or put up for Retail in 2022 were United States (US$1.4B), Portugal (US$1.23B), and Israel (US$1.2B). In the same year, the main importing countries of Medicaments (Excluding Goods of Heading 3002, 3005 or 3006) Consisting of Mixed together for Therapeutic or Prophylactic Uses, not in Measured Doses or put up for Retail were United States (US$1.36B), United Kingdom (US$1.31B), and Canada (US$881M).